HK Stock Market Move | ZHAOKE OPHTH-B(06622) rose nearly 5% during the day, and the company reached a cooperation agreement with the French pharmaceutical company FAREVA. The new drug NVK002 has recently received acceptance for market approval application.

ZHAOKE OPHTH-B (06622) rose nearly 5% during trading hours, and as of the time of writing, it has risen 3.33% to 3.1 Hong Kong dollars, with a trading volume of 9.8431 million Hong Kong dollars. On the news front, according to ZHAOKE OPHTH's official WeChat account, on July 15th, the company announced a strategic partnership with leading French pharmaceutical company FAREVA. ZHAOKE OPHTH recently signed a memorandum of understanding with FAREVA, a global manufacturer of pharmaceutical, cosmetic, and household products based in France. Under this memorandum, ZHAOKE OPHTH will become a trusted recommended partner for FAREVA customers seeking drug production in China. Additionally, ZHAOKE OPHTH recently announced that the National Medical Products Administration has accepted the new drug marketing application for NVK002 (Atropine Sulfate Eye Drops 0.02%). NVK002 is designed as a once daily eye drop for controlling the progression of myopia in children. According to statistics, there are approximately 700 million myopia patients in China, including 163 million children and teenagers. The potential commercialization of NVK002 will meet the huge demand gap in China.